# NAD and Metabolism: Insulin Sensitivity, Muscle, and Blood NAD+ in the Trials | NAD+ > NAD and metabolism: what NMN and NR did to muscle insulin sensitivity, blood NAD+, and physical performance in randomized human trials. A documented, route-tagged digest. Not medical advice. The human metabolic-muscle endpoints — muscle insulin sensitivity, blood NAD+, walking distance — documented as measured, with the species and route attached to every figure. ## In plain English This page covers what NAD and metabolism research has actually shown in people. Two precursors (building blocks the body turns into NAD+) — NMN and NR — reliably raise the amount of NAD+ in the blood when taken by mouth. The more interesting question is whether that does anything you can feel. The clearest human result so far: NMN improved muscle insulin sensitivity — how well muscle responds to insulin and takes up sugar — in one trial. Other trials report better walking and gait. None of these are doses to take; they are findings to read. ## Muscle insulin sensitivity: the clamp result The single strongest metabolic finding for any NAD+ precursor in humans is a muscle insulin sensitivity result. In prediabetic, postmenopausal women, 10 weeks of oral NMN at 250 mg/day significantly increased muscle insulin sensitivity — the capacity of skeletal muscle to take up glucose in response to insulin — measured by the hyperinsulinemic-euglycemic clamp, the reference method for this question [1]. The clamp matters because it isolates insulin action directly rather than inferring it from a fasting blood test, so the result is a clean tissue-level read, not a surrogate. The trial also found NMN remodeled insulin-signaling and gene-expression in muscle. Notably, it did **not** change body composition or HbA1c, so this is a tissue-level insulin-handling result, not a weight or glycemic-control outcome [1]. Route matters: this is an oral-precursor finding, not an effect of infused NAD+. And it is one trial in one population — a striking signal that, like the rest of this field, still needs replication before it becomes a general claim [14]. ## Nicotinamide mononucleotide (NMN): muscle insulin sensitivity and physical-performance trials NMN sits one enzymatic step from NAD+ and is the precursor most associated with the metabolic-muscle data. Beyond the clamp result, a multicenter, double-blind RCT tested 300, 600, and 900 mg/day for 60 days in healthy middle-aged adults: blood NAD+ rose significantly at days 30 and 60 across all NMN groups versus placebo (p≤0.001), walking distance improved, a biological-age measure did not rise, and 600 mg/day was identified as the optimal dose with no safety issues at any level [3]. A 2024 systematic review pooled ten randomized trials (437 participants, mean age 58, doses 150–1200 mg/day, mean follow-up 9.6 weeks) and reported statistically significant gains in gait speed (p=0.002), five-times sit-to-stand (p=0.04), six-minute walking distance, and SF-36 quality-of-life scores, with no serious adverse events [15]. In rodents, NMN at 500 mg/kg/day improved insulin sensitivity and glucose tolerance in high-fat-diet mice — a preclinical signal, not a human dose [8]. ## Why exercise is the natural NAD+ lever The metabolic story is not only about pills — it is about the salvage enzyme NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting step that recycles nicotinamide back into NAD+). Aerobic exercise induces NAMPT protein roughly two-fold higher in athletes than in sedentary subjects [7]. Mechanistically, AMPK–NAMPT signaling raises the NAD+/NADH ratio, activates SIRT1, and deacetylates PGC-1α to drive mitochondrial biogenesis (the cell building more of its energy organelles); blocking NAMPT blocks contraction-induced mitochondrial genes, and mice engineered to overexpress NAMPT showed about three-fold higher exercise endurance than wild-type [7]. NAD+ biosynthesis is also tissue-specific and clock-linked: deleting NAMPT disrupted most circadian transcripts in brown and white fat but left skeletal muscle clock function intact, despite an equivalent NAD+ drop [9]. ## Anti-inflammatory signal in aged muscle One small but mechanistically rich human trial gave NR at 1 g/day (500 mg twice daily) for 21 days to 12 aged men (median age 75). NR roughly doubled a marker of the muscle NAD+ metabolome, raised nicotinamide clearance products five-fold, and — notably for the metabolic-aging story — suppressed circulating inflammatory cytokines IL-6, IL-5, IL-2, and TNF-α, with no adverse effects observed [6]. This pairs with the consistent finding that NR raises whole-blood NAD+ dose-dependently in larger trials [4]. The honest caveat across all of this: blood and muscle NAD+ markers move reliably, but a 2025 review concluded that translation to hard clinical endpoints in humans remains limited [14]. ## Does NAD cause weight gain? No trial shows NAD+ precursors cause weight gain. In rodents, the precursor NR decreased diet-induced weight gain and liver-fat accumulation [8]. Human NMN trials reported improved muscle insulin sensitivity without measured changes in body composition [1]. Effects on human body weight are simply not established as an outcome — this is a metabolic-signaling literature, not a weight-management one. ## Does NAD help with weight loss? NAD+ precursors improved insulin sensitivity and reduced liver fat in animal models [8], and improved muscle insulin sensitivity in one human NMN trial [1], but human trials have not demonstrated weight loss as an outcome. The metabolic-muscle findings are about how tissue handles insulin and energy, not about scale weight. Treat any "NAD+ for weight loss" claim as unsupported by the controlled human record. ## Is taking NAD orally effective? Oral NAD+ itself is poorly absorbed intact, so most effective oral products are precursors — NMN and NR — which reliably and dose-dependently raise blood NAD+ in randomized trials [4][3]. Functional benefits are more mixed: muscle insulin sensitivity improved in one NMN trial [1], and physical-performance measures improved in a pooled review [15], but hard clinical outcomes remain unproven [14]. --- Documentation of the NAD+ record: the precursor trials logged green, the IV and injection gaps flagged amber, the species and route on every figure — no clinic behind the docs and nothing here dispensed, dosed, or sold.